Figure 3.

Inhibitory effect of CRGs against herpes simplex virus type 1 (HSV-1) and enterovirus (ECHO-1). Vero cells were infected with HSV-1, ECHO-1 (100 PFU/mL) and simultaneously treated with several concentrations of tested compounds. The antiviral activity of compounds was determined by plaque reduction assay and values are expressed as means ± SD of three experiments, each performed in triplicate. (A) The dose-dependent antiviral activity of CRGs (CRGs) against HSV-1 and ECHO-1 and data represented the rate of inhibition of the plaques (%). The inhibitory concentration (IC50) values of the CRGs were calculated by regression analysis of the dose–response curves; (B) Lists the IC50, cytotoxic concentration (CC50), and selectivity indices (CC50/IC50, SI) values. * Significance of the differences between the parameters of CRG polysaccharides (CRG1, CRG2 and CRG3) compared to CRG oligosaccharide (CRG4) (p ≤ 0.05).